On this episode, you’ll hear from Kenneth Davis, M.D., president and CEO of Mount Sinai Health System in New York, a system that was on the front lines of the first wave of COVID-19. He is a neurobiologist and a pioneering researcher in the field of brain disease, notably Alzheimer’s disease.

Dr. Davis discusses lessons learned during the COVID-19 pandemic and how to better prepare for further surges or another virus. In our conversation he says, “We just need to be ready,” emphasizing the necessity for the U.S. to be a leader in responding to a future global pandemic, including on diagnostic testing and vaccines.

Responding to a public health emergency of this scale reveals the benefits of working and collaborating in a large, integrated health system. Dr. Davis reflects on his system’s experience and on a range of related topics including health care inequities, social determinants of health, and using a population health model to provide care and keep people well.

Look for more of my conversations on trending topics with health care leaders from around the country, released as part of the Chair File.

Rod Hochman, M.D.
AHA Chair

 

 

Related News Articles

Perspective
With fall in full swing, there are two easy steps that individuals can take to protect themselves and their families against illness — get a flu shot and get a…
Headline
The Centers for Medicare & Medicaid Services today approved Medicaid demonstrations for Oregon and Massachusetts that will test innovative approaches…
Headline
In a study of 151 tax-exempt hospitals reported yesterday in JAMA Network Open, 84% updated their charity care policies between 2019 and 2021. Among the…
Headline
At a White House conference today on hunger, nutrition and health, the Biden Administration announced $8 billion in public- and private-sector commitments…
Headline
Pfizer has submitted a request for the Food and Drug Administration to authorize a 10-microgram booster dose of its bivalent COVID-19 vaccine booster for…
Headline
Health care providers who treat uninsured or underinsured patients with commercially procured bebtelovimab, a COVID-19 monoclonal antibody therapy for…